
Superpower peptides available for pre-order. Get first access.

Peptide science
What is pinealon (EDR)?
Pinealon (EDR) is a Glu-Asp-Arg tripeptide studied in cells and rodents. See the research, the lack of human trials, and its FDA status.
Quick answer
Pinealon (EDR) is a synthetic tripeptide, Glu-Asp-Arg (C15H26N6O8, 418.4 g/mol), from Vladimir Khavinson's bioregulator program. Evidence comes from cell and rodent studies, including one showing 11% higher dendritic spine density in Alzheimer's model mice, and from a few non-randomized human reports. Most of it comes from one research network. No randomized trial exists, and as of November 2026 it has no FDA approval.
- Published
- April 18, 2026
- Last updated
- November 12, 2026
Key takeaways
- Pinealon (EDR) is a synthetic tripeptide, Glu-Asp-Arg, from Vladimir Khavinson's bioregulator program, with the formula C15H26N6O8 and a molecular weight of 418.4 g/mol1.
- As of November 2026, pinealon is not FDA-approved for any human use and does not appear on FDA's 503A nomination lists2.
- Evidence comes from cell, rodent, and a few non-randomized human studies, mostly from one research network. Randomized controlled trials are still lacking3.
- Superpower does not offer or sell pinealon.
What is pinealon?
Pinealon, also called the EDR peptide, is a synthetic tripeptide, a short chain of three amino acids: glutamic acid, aspartic acid, and arginine. Vladimir Khavinson's St. Petersburg group developed pinealon and proposes that it influences gene activity by binding DNA. Most pinealon research has used cell cultures and rodents.
Pinealon comes from the Khavinson group's bioregulator program, which isolates short peptides from organs and builds synthetic versions two to four amino acids long4. The group's own review reports longer rodent lifespans and fewer tumors with some preparations.
Under the group's hypothesis, short peptides enter the cell nucleus and bind DNA5 to help regulate genes. Labeled pinealon entered the nuclei of cultured human cells6 and bound DNA sequences in test tubes. That step has not been shown in living animals or people.
In stressed lab-grown nerve, immune, and PC12 cells, pinealon lowered reactive oxygen species7 (cell-damaging free radicals) and reduced cell death. In cultured mouse neurons, EDR restored lost nerve-cell contact points8. Pinealon also raised serotonin expression9 in cultured brain-cortex cells, and the group has proposed a gene-regulation role in Alzheimer's disease10. Animal studies extend those cell results.
What pinealon animal studies have measured
In a small set of rat and mouse experiments, animals given pinealon fared better under induced brain stress, though one study recorded a rise in a cell-death enzyme.
| Animal model | What researchers reported | Year | Research group |
| Old rats with a blocked carotid artery, cutting blood flow to the brain | Pinealon given beforehand improved survival11; caspase-3, a cell-death enzyme, rose moderately | 2011 | Mendzheritsky group, Rostov-on-Don |
| Old rats in acute low-oxygen and cold conditions, compared with the brain drug Cortexin | Shifts in inflammatory signals12 and brain chemistry; Cortexin had the stronger effect on free-radical activity13 and caspase-3 | 2014, 2015 | Southern Federal University, with a co-author from Khavinson's institute |
| Alzheimer's model mice (5xFAD) | Dendritic spines (contact points between nerve cells) were better preserved; spine density 11% higher in hippocampal region CA114 than in mice given saline | 2021 | Khavinson's institute, with St. Petersburg Polytechnic and Kurchatov co-authors |
| Pregnant rats with high blood homocysteine | Offspring learned and oriented better15, with less free-radical buildup and cell death in cerebellar neurons | 2012 | D.O. Ott Institute, St. Petersburg, with Khavinson's institute |
These results describe stressed rodents, which leaves open what pinealon does in people.
Pinealon has no randomized controlled human trial
As of November 2026, pinealon has no randomized controlled trial3 and no published or registered Phase 1 safety study. The human reports that exist are Russian-language studies16 that describe no randomization.
One report tested pinealon and a second peptide in 32 adults with organic brain syndrome in remission17, with no control group described. Another compared 150 truck drivers with 150 metalworkers18 and reported its best peptide results when pinealon was combined with a second peptide.
Most of this research comes from Khavinson's institute or its co-publishing labs and awaits independent testing. Sleep claims attached to pinealon share that gap.
No published study has tested pinealon for sleep
As of November 2026, no published study in people or animals has tested pinealon's effect on sleep. Pinealon's name nods to the pineal gland, which releases melatonin at night19 to keep the body clock in step with daylight.
One review lists pinealon among peptides said to target circadian regulators3 but notes their lack of clinical trials. Pinealon is often discussed alongside epitalon, a related Khavinson peptide.
Pinealon and epitalon differ in sequence and research focus
Pinealon is a three-amino-acid peptide studied mainly for oxidative stress and nerve-cell survival. Epitalon, a four-amino-acid Khavinson-group peptide, is studied mainly for telomerase and lifespan.
| Peptide | Sequence | Main research target | Evidence base | US status (as of November 2026) |
| Pinealon | Glu-Asp-Arg (EDR), 3 amino acids | Gene activity in brain cells; oxidative stress | Cell and rodent studies; non-randomized human reports | Not FDA-approved; not named in the October 2026 HHS draft peptide policy |
| Epitalon | Ala-Glu-Asp-Gly (AEDG), 4 amino acids | Telomerase, the enzyme that maintains chromosome ends20 | Cell and rodent lifespan studies21; small human studies, no adequately powered randomized trial22 | Not FDA-approved; named in the October 2026 HHS draft23 compounding policy |
That difference in status comes down to how US regulators have handled each peptide.
Pinealon is not FDA-approved for any use
As of November 2026, pinealon has no FDA-approved indication for any human use and no established regulatory classification as a bulk drug substance under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Pinealon does not appear in any category of FDA's 503A nomination lists2.
Neither 2026 federal peptide action changed pinealon's status. FDA's April removal of withdrawn nominations from its Category 2 list24 did not involve pinealon. The October 30 draft HHS enforcement-discretion policy25 names six other peptides23.
Pinealon is not legally marketed for human use in the United States. Products sold online as "research use only" are not approved for human use, and no FDA review confirms their identity, purity, or sterility.
Pinealon's safety in people is unknown
Pinealon's safety in people is unknown, because no Phase 1 study has been published and its absorption, breakdown, and clearance in humans have not been measured. The 32-adult report also noted a drop in blood-forming stem cells17 and prooxidant (cell-stressing) activity. With no control group described, that report cannot show cause.
Unregulated peptide products carry a separate quality risk. Regulators seize illegal peptides, a market that includes compounds still in preclinical development26. Falsified peptides bought online have shown low purity and toxic metal contamination27, though pinealon was not among them. That makes the source of peptide information worth checking.
Where can I learn about peptides?
Much of what circulates online about pinealon goes further than its published studies do. Every guide in Superpower’s peptide library is written and fact-checked by a team of health journalists and licensed clinicians.
The science behind peptides explains what short chains like pinealon are made of and how researchers study them.
IMPORTANT SAFETY INFORMATION
Pinealon (EDR; glutamate-aspartate-arginine) is not FDA-approved for any human therapeutic indication. Superpower Health does not prescribe, sell, compound, or facilitate access to Pinealon.
Pinealon has no established regulatory pathway for human use in the United States. It has no established regulatory classification as a bulk drug substance under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Products sold online as "research use only" are not subject to FDA manufacturing oversight or quality standards.
No Phase 1 human safety study has been published. The human side effect profile, pharmacokinetic profile, and drug interaction potential are unknown.
Pinealon should not be used by anyone outside an IRB-approved clinical research study. Mechanistic considerations of particular relevance: active or suspected neurological malignancy; pregnancy or breastfeeding (no reproductive/developmental data); concurrent serotonergic medications (theoretical interaction); autoimmune neurological conditions.
Warnings: contamination risk and dosing inconsistency from unregulated gray-market sources; absence of human pharmacokinetic data; unknown long-term safety; no established therapeutic dose; preclinical findings not yet independently tested outside the originating research network and its co-publishing labs.
As of the 2026 WADA Prohibited List, Pinealon would fall under category S0 (Non-Approved Substances), which is prohibited for competitive athletes.
No FDA-approved prescribing information exists for Pinealon.
This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to Pinealon. Pinealon is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.